The Cassava saga continues as testing partner denies preparing tainted Alzheimer's data
The news keeps getting worse over at Cassava Sciences.
In a statement Friday, testing company Quanterix denied interpreting or preparing key Alzheimer’s data from Cassava that is now the subject of a citizen petition claiming the results had been falsified.
Quanterix’s version of the story goes like this:
Cassava previously engaged Quanterix’ Accelerator laboratory to perform sample testing based on blinded samples provided by Cassava. Quanterix or its employees did not interpret the test results or prepare the data charts presented by Cassava at the Alzheimer’s Association International Conference (AAIC) in July 2021 or otherwise.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.